Difficult-to-Express Proteins Market Overview
The global difficult-to-express proteins market size was valued at US$ 4,007.61 million in 2022 and is projected to reach US$ 9,052.04 million by 2030, at a CAGR of 11.0% over the forecast period 2023-2030. Key market drivers include the increasing demand for protein biologics, technological advancements, and market developments among other factors. The difficult-to-express proteins market is segmented by proteins, technology, and application.
North America is expected to contribute significantly to the market growth owing to strong research activities, growing cases of chronic diseases, and market developments in this region. Major players in the market include Reaction Biology (Cobepa), LifeSensors Inc., Lucigen (LGC Group), BioLegend, Inc. (PerkinElmer Inc.), and OriGene Technologies, Inc., among others.
The growing demand for novel treatment options including recombinant protein products for various chronic disorders is boosting the difficult-to-express proteins market growth.
Difficult-to-Express Proteins Market Drivers
Growing cases of chronic diseases cases such as cancer, diabetes, and cardiovascular diseases among others demanding novel treatment options are expected to drive the global difficult-to-express proteins market growth during the forecast period. For instance, according to the U.S. Department of Health and Human Services in 2022, approximately 1.9 million individuals were estimated to be diagnosed with cancer in the United States.
Download Free Sample: https://www.datamintelligence.com/download-sample/difficult-to-express-proteins-market
An estimated 287,850 females and 2,710 males were to be diagnosed with breast cancer, making it the most familiar cancer diagnosis. Prostate cancer was the top cancer diagnosis among males and the second most familiar diagnosis altogether with 268,490 anticipated cases. Lung and bronchus cancer was the third most familiar cancer diagnosed with an estimated 236,740 fresh cases.
Difficult-to-Express Proteins Market Challenges
The high cost of systems and difficulty in analyzing target hinders the difficult-to-express protein market growth. Also, high-quality bioactive proteins are produced at a large-scale utilizing a protein expression system. Therefore, the total production cost of bioactive proteins increases significantly due to the high cost of reagents. For instance, the Champion pET SUMO Expression System manufactured by Thermo Fisher Scientific Inc. costs USD 1,467. 40.
Difficult-to-Express Proteins Market Opportunities
The increasing advancements in technology are presenting the global difficult-to-express proteins market with lucrative growth opportunities in the forthcoming years. For instance, the introduction of a cutting-edge technology called the Microfluidic Antibody Capture (MAC) chip is employed to assess the degree of protein expression and phosphorylation at the single-cell level. Microfluidics technology advancements have offered reliable solutions for the analysis and assessment of tumorous and non-tumorous cells, presenting the market with lucrative growth opportunities in the upcoming years.
COVID-19 Impact On Difficult-to-Express Proteins Market
The pandemic has had a positive impact on the healthcare industry, including the difficult-to-express-proteins market. With several vaccine product and drug discovery campaigns underway, the protease segment has seen massive development. The SARS-CoV-2 main protease is considered a promising drug target, as it is distinct from human proteases.
The ability to express and purify the proteins in large quantities is critical for the basic research and development of pharmaceutical agents. Covid-19 is expected to positively impact the SUMO fusion synthesis segment. SUMO fusion synthesis had been used in the expression and purification of SARS-CoV. Fusion of SUMO to the N-termini of SARS-CoV proteins drastically enhances expression in Escherichia coli cells.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.
Recent Developments in the Industry
- In June 2022, LenioBio GmbH, a protein expression platform business dedicated to promoting transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell, declared the successful linear scaling of its cell-free protein synthesis (CFPS) platform, ALiCE, to an industrial scale.
- In February 2022, Tierra Biosciences, a synthetic biology corporation that boosts the rate of discovery and allows the next generation of bio-based materials, launched the Tierra Protein Platform, an industry-first eCommerce portal that facilitates customers to obtain custom proteins synthesized, validated, and shipped to them in just a few clicks.
- In November 2022, Meta Platforms, Inc., a leading corporation dedicated to developing technologies that permit people to connect, find communities, and grow businesses, designed an AI breakthrough that accelerates the protein folding process of anticipating a molecule’s shape.
Difficult-to-Express Proteins Market Segmentation
As per the research analysis, the global difficult-to-express proteins market is segmented by proteins into membrane proteins, proteases, kinases, and others; by technology into cell-free protein synthesis, prokaryotic expression systems, gene fusion systems, and others; and by applications into drug discovery, protein purification, protein therapeutics, and disease diagnostics and monitoring.
- Based on the proteins, the proteases segment is estimated to hold a 33.0% difficult-to-express proteins market share over the forecast period (2023-2030). The increase in product launches by major key players boost the segment growth. For instance, in September 2022, Creative Enzymes launched Kex2 Protease from Saccharomyces Cerevisiae, Recombinant.
Difficult-to-Express Proteins Market Geographical Classification
The global difficult-to-express proteins market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
Asia-Pacific Difficult-to-Express Proteins Market
Owing to the rapidly growing biotechnology industry in this region, the Asia-Pacific difficult-to-express protein market is estimated to exhibit a CAGR of around 11.6%. For instance, in 2022, India’s biotechnology industry crossed US$ 80.12 Bn, growing 14% from the previous year. The Indian BioEconomy has witnessed a manyfold increase in valuation in the past ten years, with COVID-19 giving the industry a much-needed push. Indian BioEconomy grew from US$ 70.2 Bn to US$ 80.12 Bn in 2021.
North America Difficult-to-Express Proteins Market
North America occupied the highest share of the difficult-to-express proteins accounting for around 41.2% in 2022 and is estimated to increase to 41.7% by 2030. This is owing to the increasing cases of chronic disorders cases in this region presenting high demand for biologics. For instance, according to the American Cancer Society, Inc. estimations, there were roughly 609,360 demises because of cancer in the US in 2022. Cancer was the second most familiar reason for death in the US, following heart disease.
Europe Difficult-to-Express Proteins Market
Owing to the increased funding s and investments by various government organizations in Europe for new drug treatment design and development the regional difficult-to-express proteins market is estimated to hold the second largest share of the market accounting for about 27.6% of the entire market in 2030.
For instance, the UK provided about USD 894.6 million in funding for experimental therapy research in October 2022. The National Institute for Health and Care Research (NIHR) is expected to distribute the funds to qualified investigations headquarters to foster an atmosphere facilitative to such therapies and patient safety research. Approximately USD 883.4m (£790m) of these funds have been granted to 20 NIHR biological research centers (BRCs) across England during the coming five years.
Difficult-to-Express Proteins Companies and Competitive Players
There are numerous international, regional, and local suppliers in the global difficult-to-express proteins industry. The competition in the local market is fierce. The vendors compete based on price, product quality, and dependability. As a result, to prosper and survive in a competitive market, suppliers must provide cost-efficient and effective products.
Major Companies
Major companies working towards the market growth include Reaction Biology (Cobepa), LifeSensors Inc., Lucigen (LGC Group), BioLegend, Inc. (PerkinElmer Inc.), OriGene Technologies, Inc., R&D Systems, Enzo Life Sciences, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc. and Merck KGaA, among others.
About us
DataM Intelligence 4 Market Research is a premier market research and business consulting firm that empowers businesses with accurate, reliable, and real-time market data and insights across a wide range of industries. Established in 2017, we have collaborated with over 750 companies, delivering valuable market intelligence for more than 6000 markets. Our expertise, extensive industry coverage, and robust research methodology have earned us the trust of our clients, making us their go-to partner for market intelligence needs.
At DataM Intelligence, we provide comprehensive, insightful, and actionable market intelligence, helping businesses navigate complex market landscapes and make informed decisions. Our dedicated team of analysts and industry experts possess in-depth knowledge and experience in their respective fields, ensuring the highest levels of accuracy and data integrity. Choose DataM Intelligence for all your market research and business consulting needs and experience the difference our commitment to excellence can make for your business.
Media Contact
Company Name: DataM Intelligence
Contact Person: Sonal Kumari
Email: info@datamintelligence.com
Phone:+1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/
